Timing clarification: Charles River is scheduled to release 2Q26 results before the market opens on Wednesday, August 5, 2026, followed by a 9:00 a.m. ET conference call. That is today, not tomorrow. This preview uses information available through the August 4 market close. [^1]
CRL enters 2Q with a relatively explicit management setup: organic revenue should remain down modestly year over year, but EPS and margins should improve sharply from a weak 1Q. Therefore, the market’s focus is likely to be less on the headline reported revenue decline—which is mechanically affected by divestitures—and more on whether:
CRL closed at $234.16 on August 4, up roughly 2% from July 1. The stock is heading into results after a modest rally rather than a major pre-earnings rerating, leaving the call’s qualitative message on 2H demand and 2027 earnings power especially important.
Management’s May outlook creates a relatively clear near-term scorecard:
| Metric | Management’s 2Q26 setup |
|---|---|
| Reported revenue growth | Mid- to high-single-digit decline YoY |
| Organic revenue growth | Low-single-digit decline YoY |
| Non-GAAP EPS | At least 30% sequential growth from 1Q’s $2.06 |
| Segment margins | Sequential improvement expected in RMS, DSA, and Manufacturing |
| Full-year organic revenue | (1.5%) to (0.5%) |
| Full-year non-GAAP EPS | $10.80–$11.30 |
| Full-year operating-margin improvement | ~120–150 bps |
The “at least 30%” sequential EPS setup implies 2Q non-GAAP EPS of at least about $2.68. This is management guidance—not a sell-side consensus estimate—and represents the most concrete threshold for the quarter. [^2]
1Q was deliberately framed as the trough in quarterly profitability. CRL reported $995.8 million of revenue, a 1.5% organic decline, a 16.3% non-GAAP operating margin, and $2.06 of non-GAAP EPS. The quarter was pressured by unusually unfavorable timing and costs:
Those items should ease in 2Q. Additionally, the May 6 divestiture of CDMO and Cell Solutions should improve Manufacturing’s profit profile, while normal seasonal improvement in DSA and biologics testing should provide an incremental tailwind. [^2]
DSA is the key segment. It represented roughly 60% of 1Q revenue and is CRL’s most important driver of the anticipated second-half return to growth.
These are constructive leading indicators, but they have not yet fully converted into reported revenue: 1Q DSA organic revenue still declined 1.4%, largely because Discovery Services remained weak and smaller-biotech revenue reflected softer bookings from the prior summer. [^2]
The most important qualitative confirmation would be:
CRL has been clear that early-stage/startup biotech remains soft, and the company cited weakness in CRADL-related activity. If biotech financing, M&A, or IPO activity fails to convert into study starts, the expected 2H DSA revenue inflection could slip. Global pharma budgets are improving but remain below historical spending norms, making the pace of conversion from proposals to bookings and revenue the more relevant indicator than general commentary about sentiment.
1Q26 performance: $596.9 million revenue; (1.4%) organic growth; 21.0% non-GAAP margin, down 290 bps year over year.
2Q focus:
The company expects a particularly meaningful DSA margin improvement later in the year as internally sourced NHP supply becomes increasingly beneficial. CRL acquired K.F. Cambodia and already controls Noveprim; management expects these assets eventually to supply most of its NHP requirements, enhancing supply security and economics. The near-term caveat is that some higher NHP costs are expected to persist through the first half, with the more significant benefit expected in 4Q. [^2]
1Q26 performance: $208.4 million revenue; (5.5%) organic growth; 24.7% non-GAAP margin, down 240 bps year over year.
The quarter was affected by the expected trough in NHP shipment volume. That timing headwind should reverse in 2Q and support both revenue and margin sequentially.
However, RMS is not a clean all-clear story. North American small-model demand was weak in 1Q, while China was the bright spot, particularly from biotech and CRO customers. Investors should separate a likely NHP-timing rebound from a genuine improvement in the underlying North American small-model market.
1Q26 performance: $190.5 million revenue; +2.9% organic growth; 25.9% non-GAAP margin, up 280 bps year over year.
Manufacturing had the best 1Q underlying growth, led by Microbial Solutions, including Endosafe and Celsis. Biologics Testing was expected to improve through the year as CRL laps a client-specific headwind.
The complication is the completed sale of CDMO and Cell Solutions. That transaction should be margin accretive, but it also removes revenue and will make reported segment growth look weaker. Investors should prioritize organic performance in Microbial Solutions and Biologics Testing, as well as the magnitude and timing of the post-divestiture margin lift.
CRL reaffirmed:
The full-year EPS range implies 5%–10% growth from 2025’s $10.28 of non-GAAP EPS despite an expected organic revenue decline. This underscores that the 2026 thesis is driven much more by portfolio actions, cost savings, mix, and buybacks than by current-year top-line growth. [^2][^3]
Management also stated that second-half operating margin should be more than 500 bps above first-half levels, with over half of that improvement attributed to acquisitions/divestitures and the European Discovery-site transaction. That is a large back-half step-up. It creates upside if delivered, but means any shortfall in 2Q execution or any softer 3Q demand commentary could pressure confidence in the annual framework.
CRL repurchased $200 million of stock in 1Q and had $800 million remaining under its authorization as of March 28. The buyback is supportive to EPS, but it was partly funded with short-term borrowing; management raised its full-year net-interest-expense outlook by approximately $8 million to $103 million–$108 million. Net leverage was 2.6x at the end of 1Q. [^2]
Key 2Q questions:
CRL’s 2Q report should be judged against a straightforward setup: sequential EPS and margin improvement should be visible; the harder question is whether the DSA booking momentum is sufficiently durable to support a revenue recovery in 2H.
A favorable report would pair EPS above the company’s implied ~$2.68 minimum, broad sequential segment-margin gains, DSA book-to-bill at or above 1x, and a confident reaffirmation of the 2H organic-growth inflection. A weaker outcome would likely involve another organic-revenue miss, muted DSA bookings/proposals, or language that shifts the expected recovery later than 3Q.
The September Investor Day is the next major strategic catalyst, but August 5 needs to establish that CRL’s refreshed portfolio and cost base are translating into the promised earnings recovery—not merely offsetting another year of weak underlying growth.
[^1]: Charles River Laboratories, “Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call,” July 15, 2026.
[^2]: Charles River Laboratories, 1Q26 earnings release and earnings-call transcript, May 7, 2026.
[^3]: Charles River Laboratories, 4Q25/full-year 2025 earnings release, February 18, 2026.